EDUCATIONAL NOTICE: Peptidings provides information for educational and research purposes only. The compounds discussed on this page are subjects of ongoing scientific investigation at varying stages of development. None of the information presented here constitutes medical advice or a recommendation for use. Consult a qualified healthcare provider before making any decisions about peptide use.
Browse by Condition
Autoimmune & Inflammatory Conditions
Inflammation is a through-line in peptide research—many compounds across multiple clusters have anti-inflammatory mechanisms as part of their biological profile. This conditions page collects the compounds with the most direct published relevance to autoimmune and inflammatory conditions: rheumatoid arthritis, inflammatory bowel disease, psoriasis, sarcoidosis, celiac disease, and related disorders.
The evidence ranges from an internationally approved immunomodulator (Thymosin Alpha-1) to a melanocortin tripeptide with zero human data (KPV). What unites them is the goal of modulating—not simply suppressing—immune and inflammatory responses.
Condition at a Glance
|
10 Compounds Researched |
1 Approved Drug |
2 Clinical Trials |
5 Pilot Data |
2 Preclinical |
|
Approved Drug FDA-approved or equivalent regulatory approval |
Clinical Trials Human clinical trial data (Phase I+) |
Pilot / Limited Human Data Small or preliminary human studies |
Preclinical Only Animal models and cell culture only |
BLUF: Bottom Line Up Front
Thymosin Alpha-1 is the only approved drug—used in 35+ countries for immune modulation, though its pivotal sepsis trial came back negative. PL-8177 has completed Phase 2 trials for ulcerative colitis, and larazotide reached Phase 3 for celiac disease before missing its primary endpoint. BPC-157 and KPV dominate the preclinical anti-inflammatory literature but lack controlled human trials. VIP has pilot clinical data in sarcoidosis. ARA-290 has completed Phase 2 trials for sarcoidosis-related neuropathy. Alpha-MSH is mechanistically central to the melanocortin anti-inflammatory pathway but is preclinical as a therapy. Glutathione addresses the oxidative stress component of chronic inflammation.
Compounds Researched for This Condition
10 compounds with published research relevant to autoimmune & inflammatory conditions. Evidence tiers reflect the strength of research for this specific condition—not the compound’s highest overall tier.
Group 1 of 3
The Immune Modulators
Compounds that tune the immune system rather than simply suppressing it—addressing the regulatory dysfunction that drives autoimmune conditions.
Group 2 of 3
The Melanocortin Anti-Inflammatories
Compounds targeting the melanocortin receptor system (MC1R, MC3R)—a central anti-inflammatory pathway upstream of multiple cytokine cascades.
|
|
Group 3 of 3
The Barrier & Signaling Anti-Inflammatories
Compounds that suppress inflammatory signaling directly—NF-κB, cytokine cascades, tight junction dysfunction, and oxidative stress.
|
|
|
||||||||||||
|
What the Research Landscape Looks Like
Autoimmune and inflammatory conditions present a particular challenge for peptide research: the goal is not to suppress the immune system (which creates vulnerability to infection) but to modulate it—restoring appropriate regulation. Thymosin Alpha-1 approaches this through adaptive immune enhancement, promoting proper T-cell differentiation. VIP and ARA-290 have taken the clinical path furthest for specific conditions (sarcoidosis in both cases). The melanocortin compounds (PL-8177, Alpha-MSH, and the fragment KPV) exploit a distinct anti-inflammatory pathway that operates upstream of multiple cytokine cascades. BPC-157 and larazotide target different aspects of barrier function and gut-associated autoimmunity.
The evidence gap here is typical of the peptide space: extraordinary preclinical results (BPC-157’s 100+ animal studies, KPV’s nanoparticle colitis data) that have not been validated in controlled human trials. Thymosin Alpha-1, PL-8177, and larazotide are the exceptions with real clinical data—though larazotide’s Phase 3 trial missed its primary endpoint, and Thymosin Alpha-1’s defining sepsis trial produced a negative primary endpoint result as well.
| Mechanism | Compounds |
|
Adaptive Immune Regulation Promoting proper T-cell maturation and immune balance to correct the regulatory dysfunction that drives autoimmune conditions. |
Thymosin Alpha-1, VIP |
|
Melanocortin Receptor Activation Engaging the MC1R and MC3R anti-inflammatory pathway—an upstream regulator of inflammatory cytokine release. |
PL-8177, Alpha-MSH, KPV |
|
Innate Repair Receptor Signaling Activating tissue-protective innate repair pathways distinct from classical immunosuppression. |
ARA-290 |
|
NF-κB / Cytokine Suppression Directly suppressing the master inflammatory transcription factor and downstream cytokine cascades. |
BPC-157 |
|
Tight Junction Regulation Restoring intestinal barrier integrity to address gut-driven autoimmune activation in celiac and IBD. |
Larazotide |
|
Antimicrobial + Immunomodulation Killing pathogens directly while also modulating the inflammatory response they trigger. |
LL-37 |
|
Antioxidant Defense Reducing oxidative stress that amplifies chronic inflammatory signaling. |
Glutathione |
Plain English
Autoimmune conditions happen when the immune system attacks the body’s own tissue. These compounds try to fix that in different ways: Thymosin Alpha-1 trains the immune system to behave properly; VIP and ARA-290 have been tested in real patients with sarcoidosis; PL-8177 has completed Phase 2 trials for ulcerative colitis; larazotide tried Phase 3 for celiac disease but missed its endpoint; BPC-157 and KPV turn down inflammatory signals in animals; Alpha-MSH sits at the top of the melanocortin anti-inflammatory pathway; LL-37 fights infection while calming inflammation; and Glutathione reduces oxidative damage. Thymosin Alpha-1, PL-8177, and larazotide have the most clinical proof. The others lean preclinical.
Related Research
Research Clusters Covering These Compounds
|
Immune Health Peptides Thymosin Alpha-1, LL-37, KPV, and VIP—compounds with distinct immunomodulatory mechanisms. |
Injury Recovery & Tissue Repair Home cluster for BPC-157, ARA-290, and other tissue-repair compounds with anti-inflammatory activity. |
Tanning & Melanocortin Peptides Alpha-MSH and PL-8177—the anti-inflammatory side of the melanocortin family. |
|
Gut Health Peptides Larazotide and the gut-focused anti-inflammatory compounds. |
Anti-Aging & Longevity Glutathione and other compounds addressing oxidative stress and age-related inflammation. |
Disclaimer: This page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. The compounds discussed are subjects of ongoing scientific research and have not been evaluated by the FDA for all applications described. Consult a qualified healthcare provider before making any decisions about your health.